Emcure Pharmaceuticals\u2019 shares declined 3 percent on Tuesday after a large block trade triggered selling pressure in early hours. Around 40.6 lakh shares, representing about 2.4 percent of the company\u2019s equity, changed hands across two block deals on the exchanges.<\/p>\n
The transaction is likely linked to Bain Capital\u2019s BC Investments, which, according to earlier reports, was expected to offload up to 2 percent of its stake in the pharma major. Emcure Pharma shares were trading at Rs 1,352 around 11 am, extending the stock\u2019s weak trend for 2025, during which it has fallen about 7.5 percent year to date.<\/p>\n
A CNBC TV18 report on Monday indicated that BC Investments (Bain Capital) had planned to sell up to 2 percent of Emcure Pharma\u2019s total equity through a block deal at a floor price of Rs 1,296.51 per share.
This price implied a 7 percent discount to Monday\u2019s closing level of Rs 1,394.10 on the NSE.<\/p>\n
The total deal value was estimated at up to Rs 493 crore, with a 90-day lock-in applicable to the shares sold. As of the end of Q2 2025, BC Asia held a 6.3 percent stake in Emcure Pharma.<\/p>\n
Final confirmation on the seller and details of the buyers will be available once exchange disclosures are published.<\/p>\n
Also Read:<\/strong> Budget May Peg FY27 Fiscal Deficit Target Modestly Lower Than 4.4%<\/a><\/em><\/p>\n Despite the stock volatility, Emcure Pharmaceuticals delivered a strong July\u2013September (Q2) quarter:<\/p>\n Net profit: Rs 243 crore, up 25.1% YoY (vs Rs 194 crore last year)<\/p>\n<\/li>\n Revenue: Rs 2,269.8 crore, up 13.4% YoY<\/p>\n<\/li>\n EBITDA: Rs 475.4 crore, up 25% YoY<\/p>\n<\/li>\n EBITDA margin: Improved to 21% (from 19%)<\/p>\n<\/li>\n<\/ul>\n The company attributed its growth to broad-based demand across key therapeutic areas, including gynaecology, cardiovascular, HIV antivirals, pain management, and increased traction in domestic and international markets. Click here to explore: Emcure Pharmaceuticals\u2019 shares declined 3 percent on Tuesday after a large block trade triggered selling pressure in early hours. Around 40.6 lakh shares, representing about 2.4 percent of the company\u2019s equity, changed hands across two block deals on the exchanges. The transaction is likely linked to Bain Capital\u2019s BC Investments, which, according to earlier reports, […]<\/p>\n","protected":false},"author":6,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[615],"tags":[],"ppma_author":[1383],"class_list":{"0":"post-17616","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stock-market-news"}," _eael_post_view_count":0,"authors":[{"term_id":1383,"user_id":6,"is_guest":0,"slug":"pradeep","display_name":"Pradeep Sangatramani","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/09\/Pradeep-Sangatramni.jpeg","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/09\/Pradeep-Sangatramni.jpeg"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/17616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=17616"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/17616\/revisions"}],"predecessor-version":[{"id":17618,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/17616\/revisions\/17618"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/17617"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=17616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=17616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=17616"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=17616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Company\u2019s Q2 Performance<\/h3>\n
\n
Momentum in the Indian formulations business and healthy demand from emerging markets through new launches and regulatory filings also supported performance.<\/p>\n
\n<\/strong><\/em>Gift Nifty<\/a>
\nFII DII Data<\/a>
\nIPO<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"